MONTVALE, N.J.–(Company WIRE)–Dec 17, 2020–
EOM Pharmaceuticals, a privately held, scientific-stage enterprise, declared nowadays the appointment of business veteran Wayne I. Danson, CPA, as Main Financial Officer and Treasurer. Mr. Danson will be liable for foremost the Company’s fiscal operations such as monetary setting up and evaluation, funds markets, investor relations, accounting, tax and treasury.
Mr. Danson has over 35 a long time of encounter in monetary management and administration. He was most lately President and Chief Executive Officer of Danson Associates, LLC, a financial advisory and company consulting organization, specializing in finance, mergers and acquisitions (M&A), small business approach, interim CEO/CFO and turnaround consulting as nicely as tax services, which he launched in 1999.
Prior to that he was a Companion in big multinational accounting corporations and a previous Chief Government Officer and Board Member of a single of the major reverse logistics businesses in the country. He co-established JDAP Capital Advisors, LLC a non-public expense administration company and established Encompass Group Affiliates, Inc., a publicly traded logistics business that as President, CEO and Chairman of the Board, he grew the organization to more than $100 million in gross sales. Mr. Danson also now serves as the Chairman of the Board of The Kid Foundation, a national charitable group committed to creating cures for all forms of children’s interstitial and subtle lung health conditions. Mr. Danson joins an accomplished govt workforce with a deep legacy in several therapeutic places as effectively as small business achievements, including:
-
Irach Taraporewala, Ph.D.:
EOM Chief Executive Officer and Director, has many achievements in drug discovery, growth and delivery, formulation, medical units, radiopharmaceutical and DNA diagnostics, and regulatory affairs. His R&D contributions span several therapeutic locations, which include ophthalmology, cancer, swelling, immunology, endocrine, CNS, infectious sickness, malaria and cachexia. Dr. Taraporewala also was the founder, CEO, President, and Board member of OHR Prescription drugs, Inc. (NASDAQ-OHRP). - Eli Goldberger: EOM’s Founder, Chairman and Chief Running Officer, a thriving entrepreneur, concentrating on advancing innovations in prescription drugs, women’s overall health, and energy.
- Shalom Z. Hirschman, M.D.: EOM Co-Founder, Chief Scientific Officer and Health-related Director, served for about 30 yrs as the Director of Infectious Health conditions and Vice Chairman of the Mount Sinai Faculty of Medicine, was a founder of Touro Higher education and the initial to understand HIV/AIDS. Dr. Hirschman also served as CEO, President, and Chief Scientific Officer of Sophisticated Viral Analysis Corp.
“Wayne brings a wealth of economic knowledge and executive management to EOM as we get ready to secure extra funding to even more spend in medical trial improvement for our guide compounds, EOM613 and EOM147, each of which have now been in Section 2 medical trials and have shown enhanced applicable medical measures and tolerability,” stated Dr. Taraporewala, EOM Chief Executive Officer and Director. “We are fortunate to have an individual of Wayne’s caliber be part of our management team and I’m delighted to have him guide our fiscal tactic and efforts at this crucial time for our escalating firm.”
“I am fired up to sign up for the seasoned and completed team at EOM as we embark on acquiring our progressive therapeutic suite of solutions designed to improve the health and wellbeing of people,” claimed Mr. Danson.
About EOM613
EOM613 is an investigational, 1st-in-class, dual-acting, broad-spectrum immunomodulator designed to provide the two an anti-inflammatory outcome at the web-site of cytokine and chemokine overactivity, and a pro-inflammatory outcome, when desired. By re-creating balance, EOM613 may possibly rescue, maintenance, and restore an immune technique that has been confronted by an invading antigen, pathogen, or virus. This dual-acting, wide-spectrum approach may perhaps prevail over a essential limitation of traditional immunomodulators. EOM613 has currently demonstrated medical improvements in a variety of ailment states, and immune-related biomarkers and typical tolerability across five Period 2 scientific trials in patients with cachexia connected with AIDS and most cancers, and in clients with rheumatoid arthritis. EOM613 is competently created from conveniently out there supplies. Scientific trials are currently being prepared to research EOM613 to deal with people with the most extreme outcomes of COVID-19 and for patients with most cancers cachexia, a chemokine-relevant human body-squandering syndrome.
About EOM147
EOM147 is becoming produced as a proprietary, freshly reformulated squalamine-primarily based eye drop, that contains a steroid-polyamine conjugate compound with broad-spectrum antimicrobial action and anti-angiogenic exercise. Supplemental scientific trials in India and Mexico are prepared to assess EOM147 in the remedy of quite a few retinal diseases that can lead to blindness, including age-similar macular degeneration (AMD) and diabetic retinopathies. The novel formulation signifies a probable breakthrough simply because it does not have to have intraocular injection into the eye and, if permitted, would be the 1st topically administered eye drop to deal with retinal conditions.
About EOM Pharmaceuticals
EOM Prescription drugs is a privately held, medical-phase pharmaceutical company with a pipeline of products that have currently shown medical relevance in many Period 2 medical trials. The Company’s mission is to go after ground breaking approaches with novel forms of modest molecule therapeutics to address the problems of some of today’s most urgent and unmet health-related desires. EOM’s pipeline is designed on proprietary improvements intended to rescue, mend, and restore wellbeing. These improvements include things like the advancement of the to start with-and-only dual-performing, wide-spectrum immunomodulator EOM613, which has the probable to handle systemic sickness because of to an powerful inflammatory immune reaction, which include COVID-19, influenza, and cancer cachexia, and its advanced formulation of EOM147, the very first potential topically administered eye drop to take care of retinal ailments. Various Phase 2 trials suggest EOM613 and EOM147 have enhanced pertinent clinical measures and are very well tolerated.
For additional info about EOM Prescription drugs, make sure you check out www.eompharma.com.
Check out resource edition on businesswire.com:https://www.businesswire.com/news/house/20201217006039/en/
Contact: Investor RELATIONS:
Eli Goldberger
EOM Pharmaceuticals
201.351.0605, ext. 2MEDIA:
Dawn Maniglia
TogoRun
917.862.5444
Search phrase: UNITED STATES NORTH America NEW JERSEY
Business Key phrase: INFECTIOUS Ailments Diabetes Scientific TRIALS OTHER Well being BIOTECHNOLOGY AIDS Normal Health and fitness PHARMACEUTICAL Overall health ONCOLOGY
Supply: EOM Prescribed drugs
Copyright Company Wire 2020.
PUB: 12/17/2020 02:50 PM/DISC: 12/17/2020 02:50 PM
http://www.businesswire.com/information/residence/20201217006039/en
More Stories
Sales Build in November as Inventories Grow
A Two-Way Communication Tool for Teachers
My 50th birthday celebrations in Amsterdam